Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Assets Average (2021 - 2025)

Historic Assets Average for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $122.2 million.

  • Aligos Therapeutics' Assets Average rose 2394.73% to $122.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.2 million, marking a year-over-year increase of 2394.73%. This contributed to the annual value of $110.8 million for FY2024, which is 2568.54% down from last year.
  • As of Q3 2025, Aligos Therapeutics' Assets Average stood at $122.2 million, which was up 2394.73% from $142.7 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Assets Average peaked at $249.2 million during Q4 2021, and registered a low of $79.3 million during Q4 2024.
  • Moreover, its 5-year median value for Assets Average was $137.0 million (2023), whereas its average is $151.8 million.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 4460.86% in 2023, then soared by 2394.73% in 2025.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Assets Average stood at $249.2 million in 2021, then tumbled by 37.65% to $155.4 million in 2022, then decreased by 23.61% to $118.7 million in 2023, then crashed by 33.22% to $79.3 million in 2024, then surged by 54.22% to $122.2 million in 2025.
  • Its Assets Average stands at $122.2 million for Q3 2025, versus $142.7 million for Q2 2025 and $110.4 million for Q1 2025.